Breast Cancer
Conditions
Keywords
Screening, Mammography
Brief summary
POC Medical Systems has developed a Point of Care system for the screening of breast cancer in the general population. Via a proprietary algorithm, the MammoAlert™ is expected to determine breast cancer's risk level for a subject by identifying the presence in plasma of known biomarkers. The present study aims to determine the Sensitivity and Specificity of the test in plasma samples of subjects of whom the status vis-à-vis breast cancer is known.
Detailed description
2400 subjects will be screened for breast cancer in seven enrolling sites across the country to ensure diverse ethnicity. Positive subjects should be confirmed breast cancer positive by Mammography and/or biopsy. Breast cancer positive samples will be compared to the control group of samples obtained from women attending clinics for non-cancerous related pathology. Both Positive and Negative Predictive Values will be evaluated to determine accuracy and sensitivity of the screening test. Subjects whose known cancer positive or negative status do not match the test report will be followed up as appropriate, on case by case basis to identify false positive and false negative results.
Interventions
OTHERMammoAlert Screening Test
Plasma obtained from blood samples will be analyzed with the MammoAlert Screening Test for the presence of known breast cancer bio-markers.
Sponsors
POC Medical Systems, Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Inclusion criteria
1. Ability to give informed consent. Written informed consent by the patient/patient's legally acceptable representative (LAR) for donating blood sample 2. Documented absence of cancer (other than Breast Cancer) 3. Documented (Mammography and/or Biopsy) diagnosis of Breast Cancer (IDC/ILC/DCIS ), any stage 4. Blood sample taken before any treatment for Breast Cancer was administered to the subject.
Exclusion criteria
1. Other malignancy besides breast cancer in the 5 years prior to obtaining the sample. 2. Therapies for breast cancer that have been administered within 1 year of obtaining the sample 3. Any condition (including psychiatric), which in the Investigator's opinion, places the patient at undue risk by participating in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Screening performance (i.e., sensitivity and specificity) | Screening performance will be calculated at 4-months | Screening performance: comprises the sensitivity and specificity of MammoAlert™. It represents the performance of the diagnostic test and is therefore independent of the prevalence of the disease in the studied sample of patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Predictive values & likelihood ratios | Predictive values & likelihood ratios will be calculated at 4-months | Positive predictive value: the probability that a subject has the disease given that the test result is positive will be estimated by: TP/(TP+FP). Negative predictive value: the probability that a subject does not have the disease given that the result of the test is negative will be estimated by TN/(TN+FN). Likelihood ratio (LR): the likelihood that a given test result would be expected in a patient with the target disorder compared to the likelihood that that same result would be expected in a patient without the target disorder. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Accuracy of test | Accuracy of test will be calculated at 4-months | The probability that the test result reflects the true disease state will be estimated as the proportion of cases for which the test result is correct: (TP+TN)/(TP+FP+TN+FN). |
| Reproducibility | Reproducibility will be calculated at 4-months | The ability of MammoAlert™ to reveal the same result when repeatedly performed on the same sample, assessed repeatedly by the same reader |
Countries
India
Outcome results
None listed